Medical risk reducing strategies for breast cancer

Similar documents
Diabetes Mellitus and Breast Cancer

Increased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017

Chapter 2 The Link Between Obesity and Breast Cancer Risk: Epidemiological Evidence

Treatment issues for women with BRCA germline mutation

Lifestyle Factors and Cancer Survivorship: Observational Findings of Weight, Physical Activity, and Diet on Survival

Soyfood Consumption and Breast Cancer Survival. Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A.

10/11/2016. Richard J. Santen, MD. Disclosures. Key Question Regarding MHT and Breast Cancer Development. NAMS 2016 Translational Science Symposium

Soyfood Consumption and Breast Cancer Survival. Xiao Ou Shu, M.D., Ph.D. Ingram Professor of Cancer Research Vanderbilt University, U.S.A.

Host Factors that Increase Breast Cancer Risk

Breast Cancer. Dr. Andres Wiernik 2017

Continuous Update Project Keeping the science current d n u h F c r a e s e r R e c d C l r o Breast Cancer 2010 Report

Breast Cancer Risk Assessment and Prevention

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

New Insights into Breast Cancer Risk Reduction

Chemo-endocrine prevention of breast cancer

4/13/2010. Silverman, Buchanan Breast, 2003

Pinkal Desai MD MPH Weill Cornell Medical College New York, NY WHI Annual Meeting, May 5-6, 2016

HEALTH CARE DISPARITIES. Bhuvana Ramaswamy MD MRCP The Ohio State University Comprehensive Cancer Center

Hormone. Free Androgen Index. 2-Hydroxyestrone. Reference Range. Hormone. Estrone Ratio. Free Androgen Index

Factors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women

WEIGHT GAIN DURING MENOPAUSE EMERGING RESEARCH

Menopause and Cancer risk; What to do overcome the risks? Fatih DURMUŞOĞLU,M.D

Tissue-selective estrogen complexes for postmenopausal women. BMS Satellite Symposium 14 nov 2015 A Pintiaux ULg

Sex Hormone Levels and Risks of Estrogen Receptor Negative and Estrogen Receptor Positive Breast Cancers

Choosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent

Patient Education. Breast Cancer Prevention. Cancer Center

Urinary Melatonin Levels and Risk of Postmenopausal Breast Cancer in the Women's Health Initiative Observational Study

REPRODUCTIVE FACTORS, ORAL CONTRACEPTIVE USE AND BREAST CANCER SURVIVAL IN YOUNG WOMEN. Katrina F. Trivers

POLYUNSATURATED FATTY ACIDS, GENETIC SUSCEPTIBILITY, AND BREAST CANCER INCIDENCE AND SURVIVAL. Nikhil K. Khankari

Endocrine Therapy of Metastatic Breast Cancer

Hormones and cancer -risks and benefits

RALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?

Breast Cancer Survivorship

EXAMINING THE RELATIONSHIP BETWEEN LEISURE-TIME PHYSICAL ACTIVITY AND THE RISK OF COLON AND BREAST CANCER: A METHODOLOGICAL REVIEW AND META-ANALYSES

Association of reproductive history with breast tissue characteristics and receptor status in the normal breast

7.10 Breast FOOD, NUTRITION, PHYSICAL ACTIVITY, AND CANCER OF THE BREAST (POSTMENOPAUSE)

Breast Cancer The PRECAMA Study. Dr. Isabelle Romieu Head, Section of Nutrition and Metabolism

Therapeutic Cohort Results

Lifestyle Recommendations for Breast and Endometrial Cancer Prevention. Objectives 3/31/2017

Lifestyle Recommendations for Breast and Endometrial Cancer Prevention

Obesity and Breast Cancer Risk

Hormone therapy in Breast Cancer patients with comorbidities

Cancer Prevention. Underlying Assumptions. Other Known Risk Factors. Other Known Risk Factors 6/25/2009

Recreational physical activity and risk of triple negative breast cancer in the California Teachers Study

DIABETES, PHYSICAL ACTIVITY AND ENDOMETRIAL CANCER. Emilie Friberg

Estrogens and progestogens

Breast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA

Cancer Genetics Unit Patient Information

BREAST CANCER AND BONE HEALTH

SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer

S e c t i o n 4 S e c t i o n4

HOW EFFECTIVE AND SAFE ARE COMPLEMENTARY AND ALTERNATIVE MEDICATIONS : AN EVIDENCE BASED ANSWER

Seigo Nakamura,M.D.,Ph.D.

Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women s Health Initiative Observational Study

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

Risk Factors for Breast Cancer

SAMPLE REPORT. Order Number: PATIENT. Age: 40 Sex: F MRN:

UPDATE: Women s Health Issues

Marco Gambacciani President Italian Menopause Society Department of Obstetrics and Gynecology Pisa University Hospital Italy

Use of Ovarian Suppression and Ablation in Breast Cancer Treatment

Manejo do câncer de mama RH+ na adjuvância: o que há de novo?

6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention

Breast Cancer: Weight and Exercise. Anne McTiernan, MD, PhD. Fred Hutchinson Cancer Research Center Seattle, WA

Mammographic density and risk of breast cancer by tumor characteristics: a casecontrol

Research Article An Estrogen Model: The Relationship between Body Mass Index, Menopausal Status, Estrogen Replacement Therapy, and Breast Cancer Risk

Mitochondrial DNA Haplogroups and Breast Cancer Risk Factors in the Avon Longitudinal Study of Parents and Children (ALSPAC)

The Ecology of Breast Cancer

Physical Activity & Cancer What We Know, What We Don t Know. Anne McTiernan, MD, PhD Fred Hutchinson Cancer Research Center Seattle, WA

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

Reproductive. Estrone sulfate Analyte Information

Molly A. Brewer DVM, MD, MS Chair and Professor Department of Obstetrics and Gynecology University of Connecticut School of Medicine

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with

Managing menopause in Primary Care and recent advances in HRT

Outline of the presentation

Supplementary Online Content

Trial: Take-Home Message: Executive Summary: Guidelines:

Natural Hormones Replacement An Evidence and Practice Based Approach

BSO, HRT, and ERT. No relevant financial disclosures

Mousa. Israa Ayed. Abdullah AlZibdeh. 0 P a g e

La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana

Southern California Center for Sexual Health and Survivorship Medicine Inc, Newport Beach, CA 3

What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland

Obesity and Breast Cancer in a Multiethnic Population. Gertraud Maskarinec, MD, PhD University of Hawaii Cancer Center, Honolulu, HI

Racial and Ethnic Disparities in the Impact of Obesity on Breast Cancer Risk and Survival: A Global Perspective 1 3

Therapeutic Cohort Results

Updates in Gynecologic Oncology. Todd Boren, MD Gynecologic Oncologist Chattanooga s Program in Women s Oncology Sept 8 th, 2018

Breast Cancer Prevention for the Population at Large

IJC International Journal of Cancer

Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies

Is It Time To Implement Ovarian Cancer Screening?

Jim Paoletti BS Pharmacy, FAARM, FIACP, Director of Education, P2P

Relationship Between Caffeine Intake and Plasma Sex Hormone Concentrations in Premenopausal and Postmenopausal Women

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea

Adipose tissue and related gynecological cancers George Valsamakis

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

Disclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent

Leveraging Prospective Cohort Studies to Advance Colorectal Cancer Prevention, Treatment and Biology

Reproductive outcome in women with body weight disturbances

Analysing research on cancer prevention and survival. Diet, nutrition, physical activity and breast cancer. Revised 2018

Estetrol, the Next Generation of Hormone Therapy: Results of a Phase 2b Dose-finding Study in Postmenopausal Women (E4 Relief)

Transcription:

Medical risk reducing strategies for breast cancer PROF. DR. H. DEPYPERE Menopause Clinic, University Hospital, Ghent, Belgium

Life expectancy in Belgium 46,6 y in 1880 and 83,8 y in 2014 2 Women Men

Aantal gevallen per 100.000 per jaar Leeftijdspecifieke incidentie invasief borstcarcinoom (SEER 1991-1995, National Cancer Institute) 500 450 400 350 300 250 200 150 100 50 0 20-29 30-39 40-49 50-59 60-69 70-79 >79 Leeftijdscategorie

ETIOPATHOGENESIS BREASTCANCER 4

DUCTLOBULAR UNIT 5

6 Mareel en Bracke

Occult breast cancer reservoir Santen model (200 days doubling time, 1.16 cm detection, 7 % prevalence) How can we prolong dormancy of subclinical tumours? Santen R et al. Horm canc, 2013; Santen R J of steroid biochemistry and molecular biology 2013.

Different breast cancer subtypes per age in the US (similar in Europe) 8

biomedische les hormonen en kanker-2016- Prof Depypere - 9

Risk factors : Endogenous estradiol Box and whiskers plots of the concentration of 17β-estradiol in breast epithelial cells of women taking aromatase inhibitors (AI, n=6), premenopausal women taking oral contraceptives (EE2, n=12), postmenopausal controls (CTL post, n=16), premenopausal controls (CTL pre, n=24), premenopausal women taking tamoxifen (TAM pre, n=6), and postmenopausal women taking tamoxifen (TAM post, n=4). (Depypere et al. Maturitas. 2015 May;81(1):42-5).

Central adiposity is associated with insulin resistance. Besides increased circulating levels of insulin, glucose and insulin-like growth factor (IGF), insulin resistance presents with increased levels of bio-available estrogen because the high-abundant insulin outcompetes estrogen binding to sexhormone binding globulin (SHBG).

pmol/mlorg estrogen levels in cancer Premenopausal Postmenopausal 2 0 1 L bloodvessel Peripheral estrogen production Estrogen synthesis in the breast F Tumour 0 O = Ovulatory L = Luteal F = Follicular Peripheral estrogen Estrogen concentration in the breast Peripheral estrogen Estrogen concentration in the breast Miller W et al.

Risk factors: BMI, more specific insulin levels. Apple shape Metabolic syndroom

The women s health initiative (WHI, initiated in 1991 by the U.S. NIH) revealed hyperinsulinemia as an independent risk factor for postmenopausal breast cancer. Insulin is in fact a known mitogen and has been shown to stimulate cell proliferation in normal breast tissue and cancer progression in human breast cancer cell lines. While the association between obesity and estrogen receptor (ER)-negative breast cancer is lower than between obesity and ER-positive breast cancer, this association indeed indicates a connection between obesity and breast cancer independent of estrogen.

Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women (Gunter et al. J Natl Cancer Inst 2009;101:48-60) Case cohort study of incident breast cancer among nondiabetic women who were enrolled in the Women's Health Initiative Observational Study (WHI-OS), a prospective cohort of 93 676 postmenopausal women. Fasting serum samples obtained at study entry from 835 incident breast cancer case subjects and from a subcohort of 816 randomly chosen WHI-OS subjects were tested for levels of insulin, glucose, total IGF-I, free IGF-I, insulin-like growth factor binding protein-3, and estradiol. In a model that controlled for multiple breast cancer risk factors including estradiol, insulin level was associated with breast cancer only among nonusers of HT (HR for highest vs lowest quartile of insulin level = 2.40, 95% CI = 1.30 to 4.41, P trend <.001). Obesity (BMI 30 kg/m 2 ) was also associated with the risk of breast cancer among nonusers of HT (HR for BMI 30 kg/m 2 vs 18.5 to <25 kg/m 2 = 2.12, 95% CI = 1.26 to 3.58, P trend =.003); however, this association was attenuated by adjustment for insulin (P trend =.40). These data suggest that hyperinsulinemia is an independent risk factor for breast cancer and may have a substantial role in explaining the obesity breast cancer relationship.

biomedische les hormonen en kanker- 2014- Prof Depypere -Prof Bracke 16

Van de Voorde J, Depypere H. Inflamm res 1999, 48, 100-101.

Proliferatie en cel cel adhesie 18 SLOW AGGREGATION ASSAY

Estrogen only WHI RR 0.77 NHS - duration? 28 835 women with hysterectomy 19 BMI <25 BMI>25 never 78 1.00 148 1.00 <5 y 45 1.03 (0.69-1.52) 54 0.96 (0.96-1.33) 5-9.9 78 1.17 (0.84-1.62) 66 0.74 (0.55-1.00) 10-14.9 94 1.18 (0.86-1.62) 94 0.97 (0.74-1.28) 15-19.9 66 1.36 (0.97-1.92) 63 1.11 (0.82-1.51) >20 80 1.77 (1.26-2.48) 65 1.25 (0.91-1.71)

Balans between insulin, estrogen, endogenous production of hormones by breast cells. Which system is dominant?

Risk factors: Alcohol 7 % increase per consumption per day.

More en core studie 2.0 1.0 Total Cases = 77 *P<.001 RR = 0.38 (95% CI = 0.24-0.58)* Placebo 5.3 per 1000 woman-years 0.0 Raloxifene 1.9 per 1000 woman-years 0 1 2 3 4 5

Percentage of women reporting one or more days of breast tenderness at week 12. BZA/CE (both doses), BZA, and placebo demonstrated similar incidences of breast tenderness. CE/MPA showed a significantly higher rates (P < 0.001 versus all other... Review Mirkin S, Pickar J Intern women health 2013 7 465-75

Total isoflavones concentration is higher in the breast glandular tissue compared to the adipose tissue 60/40. Aglycone equivalents in the breast are 22.15-770.8 pmol/g. The β- estradiol equivalents towards the estrogen β receptor were 40 + 10 times higher for the isoflavones than for 17β estradiol. Further gen expression profiles will clarify is phyto estrogens may be usefull in a preventative setting.

Risk factors 6: NULLIPARITY

birth Two years puberty pregnancy Proliferation Proliferation Proliferation Differentiation

Proliferation decreases mutation repair Carcinogen Time for DNA damage repair before DNA duplication Low Proliferation Cancer Gene cancer gene In een cel DNA High Proliferation Time for DNA damage repair before DNA duplication Normal Normal cancer gene Cancer in daughter Gene cell In elke dochter cel Permanently mutated Mutated gene Cancer in daughter Genecell

Parous woman 80-100 % type 3 lobules Nulliparous woman has 50-60 % type 1 lobules Puberty Development of the breast Pregnancy Lactation but formation Lobule Type 1 Proliferation Lobule Type 2 60 22 4 1 Lobule Type 3 Lobule Type 4

Cells at Risk Cells at Risk Cells at Risk Carcinogens

Current running study Nulligravida BRCA1/2 women breast biopsy (gene profile) Ovitrelle 12 weeks breast biopsy (gene profile) breast biopsy (6 months)

conclusion Insulin levels, glycemia, IGF-1 play an important role in the growth of subclinical tumors. Weight loss through diet improve insulin resistance. Serm s have a proven benefit. Further gen expression profiles will clarify is phyto estrogens may be usefull in a preventative setting. Stop smoking. Start moving. In patients with breast cancer, a short overnight fast of less than 13 hours was associated with a statistically significant, 36 percent higher risk of breast cancer recurrence and a non-significant, 21 percent higher probability of death from the disease compared to patients who fasted 13 or more hours per night, report University of California, San Diego School of Medicine researchers WHEL study